pylobactell
torbet laboratories ireland limited - urea (13c) - breath tests; helicobacter infections - diagnostiset aineet - tämä lääkevalmiste on tarkoitettu vain diagnostiseen käyttöön. in vivo-diagnosointiin maha-pohjukaissuolen helicobacter pylori - (h. pylori) - infektio.
somac control
takeda gmbh - pantopratsoli - gastroesofageaalinen refluksi - protonipumpun estäjät - refluksi-oireiden lyhytkestoinen hoito (esim. närästys, hapon regurgitaatio) aikuisilla.
somac 40 mg enterotabletti
takeda gmbh - pantoprazole sodium sesquihydrate - enterotabletti - 40 mg - pantopratsoli
somac 40 mg injektiokuiva-aine, liuosta varten
takeda gmbh - pantoprazole sodium sesquihydrate - injektiokuiva-aine, liuosta varten - 40 mg - pantopratsoli
somac 20 mg enterotabletti
takeda gmbh - pantoprazole sodium sesquihydrate - enterotabletti - 20 mg - pantopratsoli
lobac tabletti
sanofi-synthelabo ab - chlormezanonum,paracetamolum - tabletti - kloorimetsanoni, yhdistelmävalmisteet
somac 20 mg enterotabletti
paranova oy - pantoprazolum natricum sesquihydricum - enterotabletti - 20 mg - pantopratsoli
blenrep
glaxosmithkline (ireland) limited - belantamab mafodotin - multiple myeloma - antineoplastiset aineet - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
darzalex
janssen-cilag international n.v. - daratumumab - multiple myeloma - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. yhdessä bortetsomibin kanssa, talidomidin ja deksametasonin hoitoon aikuispotilailla, joilla on äskettäin diagnosoitu multippeli myelooma, jotka ovat oikeutettuja autologisen kantasolujen siirto. yhdessä lenalidomidin ja deksametasonin tai bortetsomibi ja deksametasoni, hoitoon aikuisille potilaille, joilla on multippeli myelooma, jotka ovat saaneet vähintään yhtä aiempaa hoitoa. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. monoterapiana aikuispotilaille, joilla oli uusiutunut ja refraktorinen multippeli myelooma, joiden aiempi hoito, mukana proteasomin estäjä ja immunomoduloivan aineen, ja jotka ovat osoittaneet taudin etenemistä viimeinen hoito. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.
sarclisa
sanofi winthrop industrie - isatuximab - multiple myeloma - antineoplastiset aineet - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.